Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines release_3bgitb7yvrcmje5ohgyfwhpa5e

by Julia M. Kittler, Jonas Sommer, Anika Fischer, Sabine Britting, Margarete M. Karg, Barbara Bock, Imke Atreya, Ludwig M. Heind, Andreas Mackensen, Jacobus J. Bosch

References

NOTE: currently batch computed and may include additional references sources, or be missing recent changes, compared to entity reference list.
Fuzzy reference matching is a work in progress!
Read more about quality, completeness, and caveats in the fatcat guide.
Showing 1 - 30 of 53 references (in 94ms)
[b0]

via grobid
The biology of uveal melanoma
Adriana Amaro, Rosaria Gangemi, Francesca Piaggio, Giovanna Angelini, Gaia Barisione, Silvano Ferrini, Ulrich Pfeffer
2017   Cancer Metastasis Review
doi:10.1007/s10555-017-9663-3  pmcid:PMC5385203  pmid:28229253 
web.archive.org [PDF]
[b1]

via grobid
Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations.
[b2]

via grobid
Treatment of metastatic uveal melanoma: Review and recommendations
Daniel M. Albert, Arysol Soltero Niffenegger, James K.V. Willson
1992   Survey of ophthalmology
doi:10.1016/s0039-6257(05)80024-4  pmid:1589858 
[b3]

via grobid
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Emma Kujala, Teemu Ma¨kitie, Tero Kivela¨
2003   Investigative Ophthalmology and Visual Science
doi:10.1167/iovs.03-0538  pmid:14578381 
web.archive.org [PDF]
[b4]

via grobid
Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma
2005   Archives of Ophthalmology
doi:10.1001/archopht.123.12.1639  pmid:16344433 
[b5]

via grobid
Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS)
2001   Archives of Ophthalmology
doi:10.1001/archopht.119.5.670  pmid:11346394 
web.archive.org [PDF]
[b6]

via grobid
Adoptive T-Cell Therapy for Cancer [chapter]
James C. Yang, Steven A. Rosenberg
2016   Advances in Immunology
doi:10.1016/bs.ai.2015.12.006  pmid:26923004 
web.archive.org [PDF]
[b7]

via grobid
MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells
J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, S. Ostrand-Rosenberg
2007   Cancer Research
doi:10.1158/0008-5472.can-06-3770  pmid:17483366 
web.archive.org [PDF]
[b8]

via grobid
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells
Jacobus J. Bosch, Uzoma K. Iheagwara, Sarah Reid, Minu K. Srivastava, Julie Wolf, Michal Lotem, Bruce R. Ksander, Suzanne Ostrand-Rosenberg
2009   Cancer Immunology and Immunotherapy
doi:10.1007/s00262-009-0729-0  pmcid:PMC2800822  pmid:19557412 
web.archive.org [PDF]
[b9]

via grobid
Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80
S. T. Haile, J. J. Bosch, N. I. Agu, A. M. Zeender, P. Somasundaram, M. K. Srivastava, S. Britting, J. B. Wolf (+ more)
2011   Journal of Immunology
doi:10.4049/jimmunol.1003682  pmcid:PMC3377446  pmid:21555531 
web.archive.org [PDF]
[b10]

via grobid
Activation of Tumor-specific CD4+T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines
Samudra K. Dissanayake, James A. Thompson, Jacobus J. Bosch, Virginia K. Clements, Peter W. Chen, Bruce R. Ksander, Suzanne Ostrand-Rosenberg
2004   Cancer Research
doi:10.1158/0008-5472.can-03-2634  pmid:14996751 
web.archive.org [PDF]
[b11]

via grobid
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes
James A. Thompson, Minu K. Srivastava, Jacobus J. Bosch, Virginia K. Clements, Bruce R. Ksander, Suzanne Ostrand-Rosenberg
2007   Cancer Immunology and Immunotherapy
doi:10.1007/s00262-007-0381-5  pmcid:PMC2810506  pmid:17724589 
web.archive.org [PDF]
[b12]

via grobid
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells
Minu K. Srivastava, Jacobus J. Bosch, Ashley L. Wilson, Martin J. Edelman, Suzanne Ostrand-Rosenberg
2010   International Journal of Cancer
doi:10.1002/ijc.25462  pmcid:PMC2947152  pmid:20473949 
[b13]

via grobid
Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol. 1998; 160:661-66.
[b14]

via grobid
Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol. 1990; 144:4068-71.
[b15]

via grobid
Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998; 58:1486-93.
[b16]

via grobid
Immunotherapy with vaccines combining MHC class II/CD80 + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ
Beth A. Pulaski, Virginia K. Clements, Matthew R. Pipeling, Suzanne Ostrand-Rosenberg
2000   Cancer Immunology and Immunotherapy
doi:10.1007/s002620050024  pmcid:PMC11037012  pmid:10782864 
[b17]

via grobid
Cutting Edge: CD4+ T Cell Help Can Be Essential for Primary CD8+ T Cell Responses In Vivo
J.-C. E. Wang, A. M. Livingstone
2003   Journal of Immunology
doi:10.4049/jimmunol.171.12.6339  pmid:14662830 
web.archive.org [PDF]
[b18]

via grobid
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
J-A Keene
1982   Journal of Experimental Medicine
doi:10.1084/jem.155.3.768  pmcid:PMC2186611  pmid:6801178 
web.archive.org [PDF]
[b19]

via grobid
Induction of a CD8+Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+T Cell Help
Sally R.M. Bennett, Francis R. Carbone, Freda Karamalis, Jacques F.A.P. Miller, William R. Heath
1997   Journal of Experimental Medicine
doi:10.1084/jem.186.1.65  pmcid:PMC2198964  pmid:9206998 
web.archive.org [PDF]
[b20]

via grobid
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Sally R. M. Bennett, Francis R. Carbone, Freda Karamalis, Richard A. Flavell, Jacques F. A. P. Miller, William R. Heath
1998   Nature
doi:10.1038/30996  pmid:9624004 
[b21]

via grobid
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Stephen P. Schoenberger, Rene E. M. Toes, Ellen I. H. van der Voort, Rienk Offringa, Cornelis J. M. Melief
1998   Nature
doi:10.1038/31002  pmid:9624005 
[b22]

via grobid
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
John Paul Ridge, Francesca Di Rosa, Polly Matzinger
1998   Nature
doi:10.1038/30989  pmid:9624003 
[b23]

via grobid
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
D. J. Shedlock
2003   Science
doi:10.1126/science.1082305  pmid:12690201 
[b24]

via grobid
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Edith M. Janssen, Edward E. Lemmens, Tom Wolfe, Urs Christen, Matthias G. von Herrath, Stephen P. Schoenberger
2003   Nature
doi:10.1038/nature01441  pmid:12594515 
web.archive.org [PDF]
[b25]

via grobid
CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells
Zhihai Qin, Thomas Blankenstein
2000   Immunity
doi:10.1016/s1074-7613(00)80218-6  pmid:10894167 
web.archive.org [PDF]
[b26]

via grobid
CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation and Function
Arata Takeuchi, Takashi Saito
2017   Frontiers in Immunology
doi:10.3389/fimmu.2017.00194  pmcid:PMC5321676  pmid:28280496 
web.archive.org [PDF]
[b27]

via grobid
Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 1998; 161:2195-200.
[b28]

via grobid
Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Friedman SM. CD4+ T-cell induction of Fas- mediated apoptosis in Burkitt's lymphoma B cells. Blood. 1996; 88:1375-82.
[b29]

via grobid
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells
Weihong Liu, Amy L. Putnam, Zhou Xu-yu, Gregory L. Szot, Michael R. Lee, Shirley Zhu, Peter A. Gottlieb, Philipp Kapranov (+ more)
2006   Journal of Experimental Medicine
doi:10.1084/jem.20060772  pmcid:PMC2118339  pmid:16818678 
web.archive.org [PDF]
Showing 1 - 30 of 53 references  next »